FREHEMGO® (denecimig) approved in the EU for haemophilia A, with a choice of monthly, every-two-weeks or weekly dosing
Read the full story on GlobeNewswire →
Opens the original article on www.globenewswire.com
Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.